O-glycans are suitable targets as novel and useful tumor markers. The structures of O-glycans in human sera from four healthy controls were precisely analyzed to obtain the reference O-glycan database. O-glycans were prepared from sera by hydrazine treatment followed by fluorescent labeling with aminopyridine and identified using twodimensional mapping, enzymatic digestion and mass spectrometry (MS) together with methanolysis and the use of newly synthesized sulfated oligosaccharides as standards. O-glycans, present at more than 0.01% of the total O-glycans, were analyzed, and 18 kinds of acidic and 2 kinds of neutral glycans were identified. NeuAcα2-3Galβ1-3N-acetylgalactosamine (GalNAc) (61-64%), NeuAcα2-3Galβ1-3(NeuAcα2-6) GalNAc (15-26%) and Galβ1-3GalNAc (6-14%) were major components while other sialylated glycans, Galβ1-3 (NeuAcα2-6)GalNAc, Galβ1-4GlcNAcβ1-6(NeuAcα2-3Galβ1-3) GalNAc and NeuAcα2-3Galβ1-4GlcNAcβ1-6(NeuAcα2-3Galβ1-3)GalNAc were relatively minor components, accounting for 1-2%. Very minor glycans accounting for 0.01-0.1% of the total include (i) the neutral glycan, Galβ1-4GlcNAcβ1-6(Galβ1-3)GalNAc, (ii) sialylated glycans, having sialyl Tn antigen, agalacto and trisialylated structures, (iii) fucosylated glycans forming blood type H antigen, blood type A antigen, blood type B antigen, Lewis X antigen and sialyl Lewis X antigen and (iv) sulfated glycans, having 6-sulfo and 3′-sulfo structures. Two kinds of clinically applied tumor markers namely sialyl Tn antigen and sialyl Lewis X antigen in healthy controls sera were revealed to be present at 0.1-0.2% of the total. However, other markers such as CA19-9 and DU-PAN-2 were not found, suggesting the relative amounts of these glycans to be <0.01%. These detailed O-glycan profiles will help to find novel carbohydrate tumor markers.
Introduction
Extensive studies of oligosaccharide structures in cancers have revealed that malignant transformation is associated with abnormal glycosylation, resulting in expression of altered carbohydrate determinants. Many altered carbohydrate determinants, including sialyl Le x (SLe x ) and sialyl Le a (SLe a ), are classified as tumor-associated carbohydrate antigens (Hakomori 1989 (Hakomori , 2002 Fukuda 1996; Kim and Varki 1997; Brockhausen 1999; Lau and Dennis 2008) . Subsequent studies have demonstrated the functional significance of aberrant glycosylation in cancer malignancy, such as in metastasis and invasion (Hakomori 1996 (Hakomori , 2002 Ono and Hakomori 2004) . Furthermore, altered carbohydrate determinants, including tumor-associated carbohydrate antigens such as CA19-9 (SLe a epiotope), CA125, DU-PAN-2 (SLe c epitope), STN (Sialyl Tn antigen) and SLX (SLe x epitope) have been utilized as useful tumor markers for the diagnosis of cancer (Del Villano et al. 1983; Canney et al. 1984; Chia et al. 1985; Kannagi et al. 1986; Takasaki et al. 1988; Motoo et al. 1991) .
Of the above, CA19-9 and CA125, are the most well-known serum tumor markers, with the former frequently used for clinical diagnosis of a variety of cancers such as pancreatic, colorectal and stomach cancers, and the latter for ovarian cancer. DU-PAN-2, which is a precursor structure of SLe a , is a tumor marker appropriate for Lewis-negative individuals, who make up 10% of the population. Because Lewis-negative individuals cannot produce the SLe a epitope (CA19-9), the serum levels of CA19-9 in these individuals are either undetectable or very low (i.e., under 1 U/mL). Hence, measurement of CA19-9 and DU-PAN-2 are recommended for Lewis-positive and Lewis-negative individuals, respectively (Narimatsu et al. 1998) . STN and SLX are used as diagnosis or prognosis marker for mucinous and lung cancers, respectively, but the frequencies of clinical application are much less than other markers. These tumor marker oligosaccharide antigens are thought to be carried on the mucins and are probably mucintype O-glycans, which have N-acetylgalactosamine (GalNAc) at the reducing end linked to polypeptide serine and threonine residues (Magnani et al. 1983; Lan et al. 1985; Lloyd et al. 1997) . STN (sialyl Tn antigen; Neu5Acα2-6GalNAc) itself is an O-glycan. Furthermore, serum glycomic analyses discovered O-glycan marker candidates for breast and ovarian cancers using mass spectrometry (MS)-based and high-pressure (or high-performance) liquid chromatography (HPLC)-based methods (Kirmiz et al. 2007; Leiserowitz et al. 2008; Storr et al. 2008) . Therefore, O-glycans are suitable targets in the search for useful clinical marker for cancers.
Detailed serum O-glycan profiles are essential for the creation of a fundamental and helpful database to allow the search for novel O-glycan tumor marker candidates. Structural analyses of serum O-glycans have previously been performed, but only major O-glycans were identified (Yamada et al. 2010) . O-glycan profiles of purified serum O-linked glycoproteins such as IgA and MUC1 have also been reported (Royle et al. 2002) . However, these O-glycan profiling data from purified serum proteins are not consistent with those of whole serum.
In this study, comprehensive analyses of O-glycans structures of sera from four healthy donors, (one sample is blood type O, two samples are blood type A and one sample is blood type B) were performed. O-glycans, which are present in relative amounts of >0.01% of the total O-glycans in serum, were qualitatively and quantitatively analyzed. This dataset will therefore help to find novel tumor markers.
Results
Preparation of pyridylaminated (PA) oligosaccharides from human serum Sera from four healthy volunteers were subjected to hydrazine treatment to liberate O-and N-glycans from glycoproteins. After re-N-acetylation, the reducing ends of the liberated O-and N-glycans were labeled with the fluorophore, 2-aminopyridine. PA-glycans were separated into acidic and neutral PA-glycans using weak anion exchange chromatography.
Structural analysis of O-linked PA-oligosaccharides of human sera The acidic and neutral PA-oligosaccharides from sera of four samples (Cases 1-4, Case1; male 53 years old, Blood type O, Case 2; male 52 years old, Blood type A, Case 3; male 35 years old, Blood type A, Case 4; female 58 years old, Blood type B) were analyzed by size-fractionation HPLC (Figure 1 ). Qualitatively very similar but quantitatively slightly different chromatographic profiles of acidic and neutral PA-oligosaccharides were obtained. PA-glycans that eluted up to 50 min were O-linked glycans and those that eluted after 50 min were mostly N-linked glycans, as judged by MS analyses. Three peaks (P1-P3) and one peak (P4) were observed to be, respectively, the major acidic and neutral PA-glycans eluting in the O-glycan area. The purpose of this study was to comprehensively analyze the O-linked oligosaccharides in serum proteins, ranging from major to very minor components. Only analyzing the major peak components failed to identify the very minor components. Hence, O-linked oligosaccharides eluting between 10 and 50 min in the first normal-phase HPLC were divided into 11 and 9 fractions of acidic (A1-A11) and neutral (N1-N9) PA-glycans, respectively, using appropriate peaks as markers (Figure 1) , with all the fractions collected ( Figure 1) . Each of the fractions was further purified by reverse-phase HPLC ( Figure 2 ). All the peaks ranging from the very major to the barely detectable, observed in the second reverse HPLC were collected, concentrated and subjected to MS analysis. The peaks that were barely detectable were at levels in the second RP HPLC of 10 fmol, which corresponds to 0.01% of the total O-linked oligosaccharides. About 70 and 50 peaks, from the acidic and neutral PA-oligosaccharides, respectively, were subjected to MS analysis. Of these peaks, 18 acidic and 2 neutral peaks were predicted to be O-linked-derived oligosaccharides, as detailed below. Other peaks, almost all of which were very minor components, were assumed to be nonglycan small molecules, and degradation products or artifacts probably due to hydrazine treatment or other experimental procedures. The elution positions, mass data and estimated composition of these oligosaccharides are presented in Table I . Because we did not have many kinds of standard O-linked PA-oligosaccharides, only N1 could be estimated to be Galβ1-3GalNAc, from comparison of the positions on the two-dimensional (2-D) map with the standards (Table II, Figure 3B ). The structures of the other 19 kinds of O-linked PA-oligosaccharides in human sera were analyzed by a combination of 2-D mapping techniques, enzymatic digestion, methanolysis and MS analyses as described below. A list of the assigned O-glycans is detailed in Table III .
Structure of A1-1, A1-2, A3, A4, A5-1, A5-3, A6-2, A7, A8-1, A10-2 and N6 A1-1, A1-2, A3, A4, A5-1, A6-2, A7 are monosialylated, A5-3 and A8-1 are disialylated PA-oligosaccharides and A10-2 is a trisialylated PA-oligosaccharide (only the MS 2 spectrum of A10-2 is shown in Figure 4A ). MS 2 analysis revealed that A1-1 and A1-2 have NeuAc-Hex-PA and NeuAc-HexNAc-PA structures, respectively (data not shown). Sialic acid linked to A1-1 was removed with α2,3-sialidase in conditions in which this enzyme specifically cleaves the α2,3 linkage (condition 1). The product corresponds to galactose on the map, but not the other hexoses glucose and mannose ( Figure 3A) . Hence, the structure of A1-1 is predicted to be NeuAcα2-3Gal, which is a possible result of base catalyzed β-elimination ( peeling) ( Table III) . A1-2 was digested with α-sialidase from Arthrobacter ureafaciens and the desialylated product shown to correspond to GalNAc, but not the other HexNAcs, GlcNAc and ManNAc ( Figure 3A) . Hence, the structure of A1-2 is predicted to be NeuAcα2-6GalNAc which is the sialyl Tn antigen. MS 2 spectra revealed the structure of A3 to be NeuAc-HexHexNAc-PA. Sialic acid is linked α2-3 to the terminal residue of A3, as determined by α2,3-sialidase digestion as described above. After sialidase digestion, the digestion product of A3 ran on the 2-D map at the same position as the reference compound Galβ1-3GalNAc, but not Galβ1-4GlcNAc, Galβ1-3GlcNAc or Manβ1-4GlcNAc ( Figure 3B ). From these results, the structure of A3 is predicted to be NeuAcα2-3Galβ1-3GalNAc. A5-3 has a NeuAc-Hex-(NeuAc)-HexNAc-PA structure, as judged by MS 2 analysis; sialic acid is linked to both the terminal hexose and the reducing end HexNAc residues. Sialic acid is linked α2-3 to the terminal hexose, as judged by sialidase specificity. The desialylated glycan produced by α2,3-sialidase was identical to A4 on the map ( Figure 3B ). Both sialic acids linked to A5-3 were digested with α-sialidase from Arthrobacter ureafaciens, and the product of the digest coincided with the position of the reference compound Galβ1-3 GalNAc ( Figure 3B ). Hence, the structures of A5-3 and A4 O-glycans in human serum were estimated to be NeuAcα2-3Galβ1-3(NeuAcα2-6)GalNAc and Galβ1-3(NeuAcα2-6)GalNAc, respectively. The structures of A6-2, A7 and A8-1 were estimated to be NeuAc-Hex-HexNAc-(Hex-)HexNAc-PA, Hex-HexNAc-(NeuAc-Hex-)HexNAc-PA and NeuAc-Hex-HexNAc-(NeuAc-Hex-)HexNAc-PA, respectively. Sialic acids of these PA-glycans are linked α2-3 to terminal hexose. Desialylated products of the three PA-glycans had a very similar behavior on the HPLC, eluting at the same positions, which is also identical to that of N6, indicating that A6-2, A7 and A8-1 have the same core2 backbone structure ( Figure 3B ). N6 and desialylated products from A6-2, A7 and A8-1 were sequentially digested with β1,4-galactosidase from Streptococcus pneumonia and β-N-acetylhexosaminidase from Jack bean. The products of these digests correspond to the reference compound Galβ1-3GalNAc on the map, indicating the structure of these backbones to be Galβ1-4HexNAc-(Galβ1-3) GalNAc, and most likely Galβ1-4GlcNAcβ1-6(Galβ1-3)GalNAc ( Figure 3B ). A5-1 was identical to the β1,4-galactosidase digested product of A7 on the map ( Figure 3B ). The MS 2 spectrum of A10-2 is shown in Figure 4A . The presence of the fragment ions Figure 3B ). A10-2 was digested with α-sialidase from Arthrobacter ureafaciens, and the product of the digest coincided with the position of Galβ1-4GlcNAcβ1-6 (Galβ1-3)GalNAc ( Figure 3B ). The structures of A6-2, A7, A5-1, A8-1 and A10-2 are predicted to be as given in Table III .
Structures of A8-2, A9-1, A9-2 and A10-3 A8-2, A9-1 and A9-2 are monosialylated, monofucosylated glycans, while A10-3 is a disialylated, monofucosylated PA-Olinked glycan all having the core2 tetrasaccharide backbone, Galβ1-4GlcNAcβ1-6(Galβ1-3)GalNAc, as described below. Because the MS 2 spectra of A8-2 and A9-2 are very similar, only the MS 2 spectrum of A9-2 is shown in Figure 4B , respectively in the MS 2 spectra of A9-2 and A8-2, indicates that A8-2 and A9-2 have a Hex-HexNAc-(NeuAc-Hex-)HexNAc-PA structure and that a fucosyl residue is linked to the Hex-HexNAc residues. Sialic acid is linked α2-3 to hexose, as determined by the above-mentioned method. After desialylation, A8-2 could be digested with α1,2-fucosidase, but not with α1,3/4-fucosidase and the position of the product of the digest on the map corresponded with that of Galβ1-4GlcNAcβ1-6(Galβ1-3)GalNAc (N6), as was determined in the above experiment ( Figure 3C ). In contrast, after desialylation, A9-2 could be digested with α1,3/4-fucosidase, but not with α1,2-fucosidase and the position of the product of the digest corresponded with that of Galβ1-4GlcNAcβ1-6 (Galβ1-3)GalNAc (N6) ( Figure 3C ). On the basis of these results, the structures of A8-2 and A9-2 are proposed to be blood type H and Lewis X antigens, respectively (Table III) . A9-1 has a NeuAc-Hex-HexNAc-(Hex-)HexNAc-PA structure, a fucosyl residue is linked to the Hex-HexNAc residues and sialic acid is linked α2-3 to hexose as evidenced by MS analysis and sialidase specificity (data not shown). The desialylated product of A9-1 could be digested with α1,3/4-fucosidase, but not with α1,2-fucosidase and the position of the product of the digest corresponded with that of Galβ1-4GlcNAcβ1-6(Galβ1-3) GalNAc ( Figure 3C ). Similarly, the structure of A10-3 was investigated by MS analysis, sialidase specificity and fucosidase digestion ( Figure 3C ). Thus, both A9-1 and A10-3 are proposed to be sialyl Lewis X structures (Table III) . , respectively in the MS 2 spectra of A5-2 and A6-1, suggests that A5-2 and A6-1 have a Hex-HexNAc-(NeuAc-Hex-)HexNAc-PA structure and a sulfate residue linked to Hex-HexNAc residues. The structure of A6-1 was determined by methanolysis and glycosidase digestion. Our preliminary experiments revealed that methanolysis under the conditions used in this study hydrolyzes 90% of the sulfate linked to galactose or GlcNAc. A6-1 was methanolyzed and the products appeared at the position of A7, suggesting that A6-1 was a sulfated form of Galβ1-4GlcNAcβ1-6(NeuAcα2-3Galβ1-3)GalNAc ( Figure 3C ). It has been reported that Jack bean β-galactosidase can hydrolyze Galβ1-4(HSO 3 -6)GlcNAc, whereas β1-4 galactosidase from S. pneumoniae cannot hydrolyze the linkage. A6-1 could be digested with Jack bean β-galactosidase, but not with β1-4 galactosidase from S. pneumoniae ( Figure 3C ) (Hemmerich et al. 1995; Murakami et al. 2007 ). Digestion of the agalacto form with human placental β-N-acetylhexosaminidase, which is able to cleave terminal HSO 3 -6GlcNAc residues, released a HexNAc-HSO 3 residue, as measured by MS, and the product of the digest coincided with the position of the reference compound NeuAcα2-3Galβ1-3GalNAc (A3), as was determined in the above experiment ( Figure 3C ). These results indicate that the sulfate residue of A6-1 is linked to the sixth position of a GlcNAc (Table III) . The structure of A5-2 is also a sulfated form of Galβ1-4GlcNAcβ1-6(NeuAcα2-3Galβ1-3)GalNAc. The linkage position of the sulfate of A5-2 was speculated to be the third position of galactose. Hence, 3′-sulfo-Galβ1-4GlcNAcβ1-6 (NeuAcα2-3Galβ1-3)GalNAc was synthesized using A7 as the substrate (see the Materials and methods section, Figure 3C ). As expected, the elution position of A5-2 on two types of HPLC (NP 3.19, RP 7.90) corresponded to that of the newly synthesized 3′-sulfo-Galβ1-4GlcNAcβ1-6(NeuAcα2-3Galβ1-3) GalNAc-PA ( Figure 3C ). The structures of A5-2 and A6-1 are listed in Table III .
Structures of A10-1 and A10-4 MS analyses revealed the backbone structures of A10-1 and A10-4 to be a monofusosylated form of Hex-HexNAc-(NeuAc-Hex-)HexNAc-PA with HexNAc and Hexose linked to the terminal hexose, respectively. Furthermore, A10-1 and A10-4 are present only in sera of Blood type A (Cases 2 and 3) and Blood type B (case 4) ( Table III) . These results strongly suggest that A10-1 and A10-4 have A-blood type and B-blood type structures, respectively. A10-1 and A10-4 were digested with α-N-acetylgalactosaminidase from Acremonium sp. and α-galactosidase from green coffee bean, respectively. Predictably, the products of both digests were identical to A8-2, which have O-blood type H antigen ( Figure 3C ). The structures of A10-1 and A10-4 are listed in Table III .
Relative ratios of O-linked PA-oligosaccharides Hydrazine treatment, predictably, gave rise to base catalyzed β-elimination (peeling) resulting in the presence of NeuAcα2-3Gal (35-42% of all glycans) (Table III, A1-1). This fragment remains after the elimination of terminal GalNAc from susceptible O-glycans (both Core 1 and Core 2 type glycans) and was therefore excluded when determining the percentage of individual glycans. Table III details the percentages of whole glycan pools and percentages once the peeling glycans (A1-1) are removed from the analysis.
Acidic glycans are dominant, making up >90% of the total O-glycans while neutral glycans are relatively minor components (<10%). All glycans, with some exceptions, were found in the sera from all four cases (Table III) . The exceptions are (1) A5-2 is found in the serum of Case 1, but not the other three cases, (2) A10-2 was found in the sera of Cases 2-4, but not in Case 1, (3) A10-1 was found in the sera of Cases 2 and 3, but not in Cases 1 and 4 and (4) A10-4 was found in the serum of Case 4, but not in other cases.
A1-1 ( peeling product), A3 (61-64%), A5-3 (15-26%) and N1 (6-14%) are the major components, and comprise the four major peaks, P1, P2, P3 and P4, respectively. A4, A7 and A8-1 are relatively minor components accounting for 1-2% of the total. The other glycans, A1-2, A5-1, A5-2, A6-1, A6-2, A8-2, A9-1, A9-2, A10-1, A10-2, A10-3, A10-4 and N6 are very minor with levels around the detection limit, accounting for 0.01-0.1% of the total.
Discussion
The structures of O-linked oligosaccharides in human sera from four healthy controls were comprehensively analyzed. We have provided precise structural information in terms of quality and quantity for 20 kinds of O-linked oligosaccharides (18 kinds of acidic and 2 kinds of neutral) that are present in relative amounts exceeding 0.01% in control sera (Table III) . When the peeling product (A1-1) is excluded from the analysis, NeuAcα2-3Galβ1-3GalNAc (A3, 61-64%), NeuAcα2-3Galβ1-3(NeuAcα2-6) GalNAc (A5-3, 15-26%) and Galβ1-3GalNAc (N1, 6-14%) are the major components. Other sialylated glycans, Galβ1-3 (NeuAcα2-6)GalNAc (A4), Galβ1-4GlcNAcβ1-6(NeuAcα2-3 Galβ1-3)GalNAc (A7) and NeuAcα2-3Galβ1-4GlcNAcβ1-6 (NeuAcα2-3Galβ1-3)GalNAc (A8-1) are relatively minor components, accounting for 1-2% of the total. Very minor species present at around the detection limit accounting for 0.01-0.1% include (1) neutral glycan, N6, (2) sialylated glycans, A1-2 (sialyl Tn antigen), A5-1 (agalacto form of A7), A6-2 and A10-2 (trisialylated glycan), (3) fucosylated glycans, A8-2 (blood type H antigen), A10-1 (blood type A antigen), A10-4 (blood type B antigen), A9-2, (Lewis X antigen), A9-1 (sialyl Lewis X antigen) and A10-3 (sialyl Lewis X antigen) and (4) sulfated glycans, A5-2 (3′-sulfo) and A6-1 (6-sulfo).
Four kinds of O-glycans (A10-1 and A10-4, A5-2 and A10-2), all of which are very minor components, were not detected in all four cases. A10-1 and A10-4 have blood type A and B structures, respectively, and are present in serum, predictably, in a blood type-dependent manner. The other two glycans (A5-2 and A10-2) are probably present in the sera of all four cases, but under the detection limit (under 0.01%) in the sera of the undetected cases (A5-2: Cases 2-4, A10-2: Case1).
Among the 20 O-glycans, two types of carbohydrate tumor markers already clinically applied were identified, namely STN (A1-2), and SLX (A9-1 and A10-3). However, other carbohydrate tumor markers such as CA19-9 (sialyl Lewis A) and DU-PAN-2 (sialyl Lewis C) could not be detected in this study, suggesting that the quantities of CA19-9 and DU-PAN-2 in healthy control sera are less than those of STN and SLX and probably <0.01% of the total O-glycans. The quantities of these carbohydrate antigens in human serum have not been compared because of the following reason. The quantities of all the carbohydrate tumor markers are measured using enzyme-linked immunosorbent assay, and the concentrations of them are described as unit/L. However, it is difficult to convert this concentration of carbohydrate antigens (unit/L) to a general concentration description, mass concentration (g/L) or molar concentration (mol/L), because a unit of carbohydrate antigen is an arbitrary unit, due to the absence of well-defined and quantified standards (Del Villano et al. 1983) . In this study, the concentrations of STN, SLX and the other glycans in the sera of healthy controls are described as the ratio relative to total O-glycans, but not g/L or mol/L (Table III) .
STN and SLX are used in clinical cases, but the frequency of clinical application is much less than for CA19-9 and DU-PAN-2. This study reveals that the normal levels of CA19-9 Fig. 3 . Two-dimensional mapping, digestion, methanolysis and sulfation of O-linked PA-oligosaccharides. Open circles indicate the positions of PAglycans in human sera. (A); A1-1 and A1-2, (B); A3, A4, A5-1, A5-3, A6-2, A7, A8-1, A10-2, N1 and N6, (C); A5-2, A6-1, A8-2, A9-1, A9-2, A10-1 A10-3 and A10-4. Dotted-line arrows (2,3-S) in (A-C) indicate the direction of the change after α2-3 sialidase digestions where the enzyme specifically digests sialic acid in the α2-3 linkage. Arrows indicate the direction of the change after glycosidase digestion except α2-3 sialidase or methanolysis of PA-glycans. Glycosidases are shown beside each line. Enzyme abbreviations are: 1,3/4-F; α1,3/4-fucosidase, 1,2-F; α1,2-fucosidase, 1,4G; β1,4-galactosidase from Streptococcus pneumonia, Hex(JB); β-N-acetylhexosaminidase from Jack bean, G; β-galactosidase from Jack bean, Hex(HuP); β-N-acetylhexosaminidase from human placenta, N; α-sialidase (neuraminidase) from Arthrobacter ureafaciens, αGalNAc: α-N-acetylgalactosaminidase, αGal: α-galactosidase. M indicates methanolysis. Broken line arrow in (C) indicates the direction of the change after 3′ sulfation of A7. This broken line is curved so as not to cross A6-1.
X marks the positions of the standard compounds. Abbreviations for standard compounds are: G4GlcNAc; Galβ1-4GlcNAc, G3GlcNAc; Galβ1-3GlcNAc, G3GalNAc; Galβ1-3GalNAc, M4GlcNAc; Manβ1-4GlcNAc. Closed circles mark the positions in sequential enzymatic digestion. Triangles in panel C represent the reference compounds, A3, N6 and A7, which were obtained in the analysis shown in (B). and DU-PAN-2 are 10 or more fold lower than those of STN and SLX (normal levels of STN 0.1% (A1-2), SLX; 0.1-0.2% (A9-1 + A10-3), CA19-9 and DU-PAN-2 probably less than 0.01%). These findings raise the possibility that one of the important factors in determining the usefulness of tumor markers might be their normal levels in healthy control serum. For example, even though albumin, the most abundant serum protein, is produced in cancers and leaks into blood, albumin is never a useful tumor marker. Serum substrates, present in lower levels in a healthy control, might be the more promising tumor marker candidates. Higher normal levels of STN and SLX might be an attribute of less useful tumor markers than CA19-9 and DU-PAN-2. In this study, large amounts of peeling product (A1-1) are observed. It is one of the major products and comprises 35-42% of the total. It is essential to reduce the peeling process in order to obtain more reliable results. Recently, Kozak et al. (2012) reported that peeling can be greatly reduced when the sample is buffer changed prior to hydrazine treatment to solutions of either 0.1% trifluoroacetic acid (TFA) or low-molarity ethylenediaminetetraacetic acid (EDTA). In future, innovative methods to reduce the peeling products are urgently required.
O-glycans in human serum
The structures of O-glycans of several kinds of purified serum proteins have been analyzed. However, these O-glycan profiling data from the purified serum proteins are not consistent with those of whole serum. Secretory IgA contains at least 25 different O-glycans in its hinge region (Pierce-Cretel et al. 1989; Royle et al. 2002) . In contrast to O-glycans from whole serum proteins, neutral oligosaccharides are dominant (70%). Secretory IgA has O-glycans having an elongated and/ or branched backbone such as Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-6(Galβ1-3)GalNAc or Galβ1-4GlcNAcβ1-3 (Galβ1-4GlcNAcβ1-6)Galβ1-4GlcNAcβ1-6(Galβ1-3)GalNAc at relatively high levels. Some of the fucosylated structures were found to have Lewis A, Lewis B and Lewis X structures. Royle et al. (2002) A: Percent of individual glycan relative to all glycans, R: percentage of individual glycans when the peeling glycan (A1-1) is removed from analysis.
human neutrophil gelatinase B, where 18 kinds of O-glycans were identified. In neutrophil gelatinase B, acidic glycans are dominant, and several kinds of O-glycans having the hexasaccharide backbone Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-6(Galβ1-3)GalNAc, with or without Lewis X antigen, were present at relatively low levels. These elongated species were not detected in this study. Human apolipoprotein CIII is a small glycoprotein with a single mucin-type core 1 oligosaccharide. The structural analysis of O-glycans of serum apolipoprotein CIII using MS revealed that monosialylated glycans (corresponded to A3 and A4 in this study) and disialylated glycan (A5-3) are dominant with neutral glycan (N1) being a minor component (Wada et al. 2012) . Storr et al. (2008) reported that O-glycans of secretory MUC1 purified from an advanced breast cancer patient's serum are mainly composed of Core 1 type and Core 2 type O-glycans (A3, A4, A5-3, A7, N1, N6 in this study). In addition to these glycans, four glycans that were not detected in this study were identified: two Core 2 type glycans that have a sialic acid residue α2-6-linked to galactose and two Core 1 type glycans that have a sialic acid residue α2-8-linked to sialylated core 1 type structures. In this study, O-glycans were liberated from serum glycoproteins and their structures were extensively analyzed. However, no information concerning the proteins carrying each O-glycans is provided. The structures of serum O-glycans accounting for >1% of the total are very simple and general. Hence, these glycans are likely to be attached to a variety of O-glycosylated proteins, which are probably not special or limited kinds of proteins. In contrast, the very minor species accounting for <0.1% of the total are likely to be attached to a limited number of proteins rather than to a variety of proteins. However, while a variety of sialylated and/or fucosylated O-glycans were identified from serum proteins, little is known about the serum proteins carrying the very minor O-glycans, such as STN and sialyl Lewis X structures. Studies of isolation or immunohistochemistry of minor glycans may help to identify their carrier proteins. For example, STN was isolated from human colonic mucin (Podolsky 1985) . Furthermore, the goblet cells of human normal colonic mucosa and adenocarcinoma cells of several kinds of human cancers are strongly stained with anti STN antibody (Kjeldsen et al. 1988; Ogata et al. 1995) . It is, therefore, possible that STN-linked glycoproteins in serum are derived from these mucins in the gasctrointestinal tract.
A large amount of attention needs to be paid to contamination with oligosaccharides that are not derived from serum glycoproteins to understand the amounts of O-glycans in serum demonstrated in this study. The presence of free oligosaccharides in human sera has been reported (Iwatsuka et al. 2013) . In addition to glycans liberated from glycoproteins by hydrazine treatment, the free oligosaccharides are included in this analysis. The free oligosaccharides in sera are mostly composed of N-glycans. Two kinds of free O-glycans, corresponding to A3 and A4 in this experiment, are present as very minor components. The amounts of A3 and A4 in 10 μL serum as demonstrated in this study are 500 and 13 pmol, respectively. The amount of free O-glycans corresponding to A3 and A4 in 10 μL serum is reported to be 2-3 pmol. Hence, the amount of free O-glycans is much smaller than that liberated from glycoproteins. Furthermore, it is possible that degradation products of hydrazine treatment are included in this analysis. In particular, A1, NeuAcα2-3Gal, which lacks GalNAc at the reducing terminal, may be a result of peeling products of O-glycans and degradation products from glycolipid and N-glycans. However, most of the sialic acid residues are α2-6-linked, but not α2-3, to galactose (forming NeuAcα2-6Gal) in N-glycans in human serum. In this study, glycans α2-6-sialylated to galactose were not found. Thus, the amount of degradation products from N-glycans is thought to be very small. As with N-glycans, the amount of degradation products from glycolipids is also thought to be very small, but further studies are warranted.
This study provides fundamental data with respect to O-glycan structures in healthy control sera, which is useful for finding carbohydrate tumor markers. If O-glycan structures in the serum of cancer patients are analyzed using similar experimental procedures as in this study and O-glycans detected that are absent in the normal serum profile, the glycans can be thought of as being increased in cancer patients and considered as carbohydrate tumor marker candidates. To this end, we are currently analyzing the O-glycan structures from sera of several kinds of cancer patients. Preparation of PA-glycans from human sera In our preliminary experiment, O-glycans of human sera were liberated by treatment with two kinds of reagents, namely hydrazine and LiOH, and the recovery and ratios of peeling products of the total O-glycans were compared between the two conditions. The recovery of O-glycans treated with hydrazine was about five times higher than when treated with LiOH, while ratios of peeling products in total O-glycans did not differ between the two conditions. Hence, in this experiment, hydrazine was selected as the reagent to liberate the O-glycans from the glycoproteins. Twenty microitres of sera were lyophilized before hydrazine treatment. O-glycans and N-glycans were liberated from the glycoproteins by hydrazine treatment at 60°C for 16 h and then re-N-acetylated with acetic anhydride in a saturated sodium bicarbonate solution as previously described (Natsuka and Hase 1998) . The reducing ends of the liberated O-glycans and N-glycans were labeled with a fluorophore, 2-aminopyridine, by reductive amination (Natsuka et al. 2011 ). The excess reagents were removed using a GlykoClean S-plus Cartridge (ProZyme, Hayward, CA) according to the manufacture's protocol. PA-glycans were further purified using a graphite carbon cartridge (GL-Pak carbograph 300 mg; GL Science Ltd, Tokyo, Japan) (Natsuka et al. 2011 ). The glycan mixture was dissolved in 0.5 mL of 50 mM ammonium acetate, pH 6.0, and loaded onto the cartridge. After washing with 5 mL of 50 mM ammonium acetate, pH 6.0, the glycans were eluted using 5 mL of 60% acetonitrile in the ammonium acetate buffer. To remove the PA-glucose and nonsugar materials, the glycan mixtures were further purified using reverse-phase HPLC. Reverse-phase HPLC was performed on a TSK gel octa decyl silyl (ODS)-80Ts column (0.2 × 15 cm, Tosoh, Tokyo, Japan) at 30°C at a flow rate of 0.2 mL/min using two solvents, A and B. Solvent A was 50 mM acetic acid, adjusted to pH 6.0 with triethylamine. Solvent B was 50 mM acetic acid containing 20% acetonitrile, adjusted to pH 6.0 with triethylamine. The column was equilibrated with solvent A. After injection of sample, the proportion of solvent B was programmed to increase linearly from 0 to 4% in 12 min, and then held at 100% for 10 min. PA-oligosaccharides were detected by excitation at 315 nm and emission at 400 nm. Fractions between 12 and 18 min after injection were collected and concentrated. These fractions had glucose unit (Gu) values of >1.5 and hence contained all of the PA-O-glycans and PA-N-glycans.
Materials and methods

All
Separation of PA-glycans and MS analysis PA-oligosaccharides were separated on a Shimadzu LC-20A HPLC system equipped with a Waters 2475 fluorescence detector. Weak anion exchange HPLC was performed at 30°C on a TSKgel DEAE-5PW column (0.75 × 7.5 cm. Tosoh, Tokyo, Japan) at a flow rate of 0.8 mL/min. The solvents used were (A) aqueous ammonia, pH 9.0, and (B) 1 M ammonium acetate buffer, pH 9.0. The column was equilibrated with 100% solvent A and, after sample injection, solvent A was held at 100% for 0.5 min, and then solvent B was linearly increased to 14% in 17.5 min and then to 100% in 12.5 min. Fluorescence was monitored using excitation and emission wavelengths of 310 and 380 nm, respectively. The following experimental procedures, including normal-phase HPLC, reverse-phase HPLC and mass analysis, have been reported previously ). Normal-phase HPLC was performed on a TSK gel Amide-80 column (0.2 × 25 cm, Tosoh). The molecular size of each PA-oligosaccharide is given in Gu based on the elution times of PA-isomaltooligosaccharides. Reverse-phase HPLC was performed on a TSK gel ODS-80Ts column (0.2 × 15 cm, Tosoh). The retention time of each PA-oligosaccharide is given in Gu based on the elution times of PA-isomaltooligosaccharides. Thus, a given compound on these two columns provides a unique set of Gu (amide) and Gu (ODS) values, which correspond to coordinates on the 2-D map. PA-oligosaccharides were analyzed by nanoLC/ESI MS/MS according to our previously established procedures (Korekane et al. 2007 ). In brief, highperformance liquid chromatography was performed on a Paradigm MS4 equipped with a Magic C18 column (0.2 × 50 mm; Michrome BioResource, Auburn, CA). MS analyses were performed using an LCQ ion trap mass spectrometer (Thermo Finnigan, San Jose, CA). In the LCQ method file, the LCQ was set to acquire a full MS scan between 400 and 2000m/z followed by MS/MS scans in a data-dependent manner.
Glycosidase digestions
Sialyl PA-oligosaccharides were digested with 2 U/mL of α2,3-sialidase from Salmonella typhimurium (Takara Bio, Inc.) or 2 U/mL of α-sialidase from Arthrobacter ureafaciens (Nacalai, Kyoto, Japan) in 100 mM sodium acetate buffer, pH 5.5, for 2 h at 37°C (Condition 1). Under these conditions, α2,3-sialidase specifically digests sialic acid α2-3 linked to the terminal residue, but not sialic acid with a α2-6 linkage while Arthrobacter α-sialidase digests both linkages independent of the linkage position. However, under conditions using 10 U/mL O-glycans in human serum
